Envestnet Asset Management Inc. Purchases 229,661 Shares of Grifols, S.A. $GRFS

Envestnet Asset Management Inc. increased its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 80.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 515,853 shares of the biotechnology company’s stock after purchasing an additional 229,661 shares during the period. Envestnet Asset Management Inc. owned about 0.08% of Grifols worth $5,138,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brandes Investment Partners LP raised its position in Grifols by 8.9% in the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after purchasing an additional 2,294,113 shares in the last quarter. Vinva Investment Management Ltd bought a new stake in shares of Grifols in the 2nd quarter valued at approximately $256,000. New York State Common Retirement Fund raised its holdings in shares of Grifols by 5.6% in the 3rd quarter. New York State Common Retirement Fund now owns 2,589,406 shares of the biotechnology company’s stock worth $25,790,000 after buying an additional 136,678 shares in the last quarter. State of Wyoming bought a new position in shares of Grifols during the 2nd quarter worth approximately $1,729,000. Finally, Norges Bank bought a new position in shares of Grifols during the 2nd quarter worth approximately $17,538,000.

Grifols Price Performance

Grifols stock opened at $9.40 on Monday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.93 and a current ratio of 2.48. Grifols, S.A. has a 1 year low of $6.19 and a 1 year high of $11.14. The company’s 50-day moving average is $9.21 and its two-hundred day moving average is $9.39.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GRFS. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research note on Thursday, January 22nd. JPMorgan Chase & Co. dropped their target price on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research report on Monday, December 8th. Wall Street Zen upgraded shares of Grifols from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Finally, Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Four equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Grifols has a consensus rating of “Hold” and a consensus price target of $10.00.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.